STOCK TITAN

DiaMedica Therapeutics Inc. - $DMAC STOCK NEWS

Welcome to our dedicated page for DiaMedica Therapeutics news (Ticker: $DMAC), a resource for investors and traders seeking the latest updates and insights on DiaMedica Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect DiaMedica Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of DiaMedica Therapeutics's position in the market.

Rhea-AI Summary
DiaMedica Therapeutics resumes ReMEDy2 clinical trial after FDA lifts clinical hold. Completed $37.5M private placement. Cash runway into 2026. Completed additional safety cohort of ACEi patients in Phase 1C study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.4%
Tags
-
Rhea-AI Summary
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced the release of its second-quarter 2023 financial results on August 14th, followed by a live conference call on August 15th to discuss business updates. The company is currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.39%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.91%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.53%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.91%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.91%
Tags
Rhea-AI Summary
DiaMedica Therapeutics announces the appointment of Dr. Richard Kuntz to its Board of Directors. Dr. Kuntz brings deep expertise in stroke treatment and has a strong background in the medical field.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.18%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.77%
Tags
-
Rhea-AI Summary
DiaMedica Therapeutics Inc. will release its first quarter 2023 financial results on May 15th and host a conference call on May 16th to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.61%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.18%
Tags
management
DiaMedica Therapeutics Inc.

Nasdaq:DMAC

DMAC Rankings

DMAC Stock Data

113.87M
23.82M
26.71%
22.01%
0.53%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
MINNEAPOLIS

About DMAC

diamedica therapeutics is a clinical-stage biopharmaceutical company that is developing innovative treatments where there is significant unmet clinical need or where no current therapies are available with the focus on neurological and kidney diseases. for more information please visit www.diamedica.com.